spacer
home > pmps > winter 2002 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

The last 12 months have been something of a roller-coaster ride, with some big 'downs' and a few small 'ups'. Just now, we are in a tunnel waiting to find out what lies ahead. Overshadowing the economic climate post September 11th, there have been spectacular crashes like that of Enron Corp., largely due to voodoo accounting practices. Events such as these are a healthy reminder that leveraging earnings to achieve growth also increases risk. So far, the pharmaceutical industry has seemed immune from similar troubles, while the big merger of Pharmacia and Pfizer looks set to create the first mega-pharma company. M&A deals are pharma's attempt to regain shareholder value. However, the news is grim for employment prospects as the industry braces itself for yet more job losses in the wake of post-merger restructuring.


Earlier in the year, analysts predicted improved prospects for manufacturing which could have helped the production sector in pharma and biotech. Outsourced pharmaceutical manufacturing has proved remarkably resilient. It's as well that the industry has the support of a robust infrastructure enabling it to deliver quality products at costs that are lower than that of in-house manufacturing - as long as similar accounting standards are used to compare them. Is this golden scenario about to change to base metal, to match the leaden skies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Patricia Lobo, Rebecca Cavalôt
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Rebecca Cavalôt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation

At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement